Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare Inc (SRTS) delivers innovative superficial radiation therapy solutions for non-melanoma skin cancers and keloid treatment. This news hub provides investors and medical professionals with essential updates on the company's FDA-cleared devices, clinical advancements, and strategic partnerships.
Access timely updates on treatment protocol developments, technology enhancements, and market expansion initiatives. Our curated news collection features regulatory milestones, peer-reviewed study results, and operational updates directly impacting the dermatology and radiation oncology sectors.
Key focus areas include new device clearances, clinical efficacy data, partnership announcements with healthcare providers, and innovations in non-invasive treatment delivery. All content undergoes rigorous verification to ensure accuracy in reporting medical device developments.
Bookmark this page for consolidated access to SRTS's latest advancements in targeted radiation therapy. Return regularly for verified updates on this pioneering medical technology company's progress in transforming skin condition treatment protocols.
On September 9, 2022, Sensus Healthcare (Nasdaq: SRTS) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, in New York City. Management will deliver a company overview and conduct one-on-one meetings with investors. A webcast of the presentation will be accessible on-demand starting September 12, 2022, at 7:00 a.m. ET on Sensus Healthcare’s website. The company specializes in innovative, non-invasive treatments for various conditions, particularly using its proprietary superficial radiation therapy technology.
Sensus Healthcare (Nasdaq: SRTS) announced the appointment of Dr. Mohammad K. Khan to its Medical Advisory Board, expanding its expertise in non-invasive treatment for oncological and non-oncological conditions. Dr. Khan, a renowned radiation oncologist at Emory University, specializes in various cancers and aims to enhance Sensus's Superficial Radiation Therapy (SRT) offerings. CEO Joe Sardano expressed optimism about Dr. Khan's contribution to market development for their innovative medical devices. This appointment underscores Sensus's commitment to advancing patient care through expert guidance.
Sensus Healthcare (Nasdaq: SRTS) has upgraded its SRT-100 Vision™ system with new solid-state High-Frequency Ultrasound technology. This enhancement includes an ergonomic probe for improved handling, allowing visualization of all skin layers, crucial for skin lesion treatment. The system also features electronic medical record capabilities for accurate image capture. CEO Joe Sardano highlighted the increased productivity and resolution of the new system, which is available immediately. Existing customers can upgrade by contacting their sales representatives.
Sensus Healthcare, Inc. (SRTS) reported strong financial results for Q2 2022, achieving revenues of $12.1 million, a 124% increase from Q2 2021. The net income for the quarter was $3.5 million, or $0.21 per diluted share, a significant turnaround from a net loss of $(0.3) million in the previous year. Adjusted EBITDA reached $4.7 million, compared to $(0.1) million in 2021. The company ended the quarter with $33.7 million in cash. Sensus affirms expectations for full-year profitability and highlights strong interest in its new TransDermal Infusion System™.
Sensus Healthcare (Nasdaq: SRTS) has sold 10 Transdermal Infusion Systems™ to Hair Enhancement Centers (HEC) in Texas, aimed at non-invasive hair health treatments. The first two systems will be delivered in Q3 2022, followed by the rest in Q4. This system enables painless delivery of U.SK Under Skin's Skin Savers Hair™ serum deep into hair follicles, enhancing patient satisfaction and treatment results. HEC has rapidly expanded from 2 to 9 clinics in 2022, providing hair loss treatments to millions of affected Americans.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on August 4, 2022, at 4:30 p.m. ET to discuss its second-quarter 2022 financial results. The management will also provide a business update and details on recent and upcoming milestones. The call can be accessed via phone or live webcast. Following the call, a replay will be available until September 3, 2022. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, featuring proprietary low-energy X-ray technology known as superficial radiation therapy.
Sensus Healthcare, Inc. (Nasdaq: SRTS) has expanded its partnership with Colorado State University (CSU) by supplying a second SRT-100™ system for the study of superficial radiation therapy (SRT) in horses. This initiative takes place at CSU's Johnson Family Equine Hospital, aiming to investigate ophthalmic indications. With SRT showing promising results in earlier studies on other animals, the potential market for veterinary applications is significant, considering there are around 30,000 veterinary practices in the U.S. The CSU team hopes to publish their findings next year.
On May 18, 2022, Sensus Healthcare (Nasdaq: SRTS) announced its participation in the H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022. The company will present on May 25 at 9:30 a.m. Eastern time, with the presentation available live and archived on its website. Additionally, Sensus management, including President Michael Sardano and CFO Javier Rampolla, will hold one-on-one meetings with investors during the conference. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing proprietary low-energy X-ray technology.
Sensus Healthcare (SRTS) reported first quarter 2022 revenues of $10.3 million, a 237% increase compared to the previous year. Net income surged to $16.1 million, or $0.97 per diluted share, thanks to a $12.8 million gain from asset sales. The company exited the quarter with $32.8 million in cash. Adjusted EBITDA improved to $16.9 million, up from a loss of $0.8 million year-on-year. Sensus affirms expectations for continued growth and profitability in Q2 and the full year.